CompletedEUCTR 2007-001611-32
A multi-center cardiac safety study of subjects who participated in Organon sponsored Phase 1 and Phase 2 completed and discontinued trials with Org 24448 (Protocols: 22601;22602;22603; 153001;1530...
This historical record does not confirm current site availability.
Historical research recordNetherlandsSchizophrenia
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Netherlands
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 295
- Sponsor
- NV Organon
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Netherlands
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2007-001611-32
- Official title
Show the full official title
A multi-center cardiac safety study of subjects who participated in Organon sponsored Phase 1 and Phase 2 completed and discontinued trials with Org 24448 (Protocols: 22601;22602;22603; 153001;1530...
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Netherlands
Registry details
Historical country statuses
- Netherlands — Completed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is NV Organon.
Want to explore more studies?
Explore studiesRelated studies
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Pa...
A phase III randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophren...